These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 37731028)

  • 1. Oestrogen receptor-independent actions of oestrogen in cancer.
    Gopinath P; Oviya RP; Gopisetty G
    Mol Biol Rep; 2023 Nov; 50(11):9497-9509. PubMed ID: 37731028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells.
    Borley AC; Hiscox S; Gee J; Smith C; Shaw V; Barrett-Lee P; Nicholson RI
    Breast Cancer Res; 2008; 10(6):R103. PubMed ID: 19055788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer.
    Poulard C; Jacquemetton J; Trédan O; Cohen PA; Vendrell J; Ghayad SE; Treilleux I; Marangoni E; Le Romancer M
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31195751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
    Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERα to inhibit the growth of breast cancer induced by oestrogen.
    Zhang N; Sun P; Xu Y; Li H; Liu H; Wang L; Cao Y; Zhou K; TinghuaiWang
    Cancer Lett; 2021 Feb; 498():54-69. PubMed ID: 33069770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
    Gee JM; Robertson JF; Gutteridge E; Ellis IO; Pinder SE; Rubini M; Nicholson RI
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S99-S111. PubMed ID: 16113104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer.
    Fan P; Agboke FA; Cunliffe HE; Ramos P; Jordan VC
    Eur J Cancer; 2014 Nov; 50(16):2866-76. PubMed ID: 25204804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor - oestradiol crosstalk and mammary gland tumourigenesis.
    Hawsawi Y; El-Gendy R; Twelves C; Speirs V; Beattie J
    Biochim Biophys Acta; 2013 Dec; 1836(2):345-53. PubMed ID: 24189571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.
    Nardone A; Weir H; Delpuech O; Brown H; De Angelis C; Cataldo ML; Fu X; Shea MJ; Mitchell T; Veeraraghavan J; Nagi C; Pilling M; Rimawi MF; Trivedi M; Hilsenbeck SG; Chamness GC; Jeselsohn R; Osborne CK; Schiff R
    Br J Cancer; 2019 Feb; 120(3):331-339. PubMed ID: 30555156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A; Howell SJ; Clarke R; Anderson E
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer.
    Patani N; Martin LA
    Mol Cell Endocrinol; 2014 Jan; 382(1):683-694. PubMed ID: 24121024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen.
    Hurtado A; Holmes KA; Geistlinger TR; Hutcheson IR; Nicholson RI; Brown M; Jiang J; Howat WJ; Ali S; Carroll JS
    Nature; 2008 Dec; 456(7222):663-6. PubMed ID: 19005469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
    Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
    J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation.
    Chan CM; Martin LA; Johnston SR; Ali S; Dowsett M
    J Steroid Biochem Mol Biol; 2002 Aug; 81(4-5):333-41. PubMed ID: 12361723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease.
    Simigdala N; Pancholi S; Ribas R; Folkerd E; Liccardi G; Nikitorowicz-Buniak J; Johnston SR; Dowsett M; Martin LA
    Br J Cancer; 2018 Aug; 119(3):313-322. PubMed ID: 29991699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards Unravelling the Role of ERα-Targeting miRNAs in the Exosome-Mediated Transferring of the Hormone Resistance.
    Andreeva OE; Sorokin DV; Mikhaevich EI; Bure IV; Shchegolev YY; Nemtsova MV; Gudkova MV; Scherbakov AM; Krasil'nikov MA
    Molecules; 2021 Nov; 26(21):. PubMed ID: 34771077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway.
    Dorssers LC; van Agthoven T; Brinkman A; Veldscholte J; Smid M; Dechering KJ
    Breast Cancer Res; 2005; 7(1):R82-92. PubMed ID: 15642172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.
    Dowsett M; Johnston S; Martin LA; Salter J; Hills M; Detre S; Gutierrez MC; Mohsin SK; Shou J; Allred DC; Schiff R; Osborne CK; Smith I
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S113-7. PubMed ID: 16113087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells.
    Murphy LC; Peng B; Lewis A; Davie JR; Leygue E; Kemp A; Ung K; Vendetti M; Shiu R
    J Mol Endocrinol; 2005 Apr; 34(2):553-66. PubMed ID: 15821116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.